Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
March 28, 2024 09:23 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present...
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
March 27, 2024 16:41 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
March 07, 2024 10:32 ET
|
Vaxxinity, Inc.
LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from its...
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
February 15, 2024 08:00 ET
|
Vaxxinity, Inc.
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of...
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
February 13, 2024 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present...
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
January 30, 2024 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research...
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
January 18, 2024 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with...
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
January 03, 2024 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief...
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
November 13, 2023 18:50 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and...
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 08, 2023 08:30 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for...